197 related articles for article (PubMed ID: 22901944)
21. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
22. Improved virus removal in ceramic depth filters modified with MgO.
Michen B; Fritsch J; Aneziris C; Graule T
Environ Sci Technol; 2013 Feb; 47(3):1526-33. PubMed ID: 23286835
[TBL] [Abstract][Full Text] [Related]
23. A novel approach to achieving modular retrovirus clearance for a parvovirus filter.
Stuckey J; Strauss D; Venkiteshwaran A; Gao J; Luo W; Quertinmont M; O'Donnell S; Chen D
Biotechnol Prog; 2014; 30(1):79-85. PubMed ID: 24123923
[TBL] [Abstract][Full Text] [Related]
24. Achieving high mass-throughput of therapeutic proteins through parvovirus retentive filters.
Bolton GR; Basha J; Lacasse DP
Biotechnol Prog; 2010; 26(6):1671-7. PubMed ID: 20859931
[TBL] [Abstract][Full Text] [Related]
25. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
26. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
27. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process.
Barnette D; Roth NJ; Hotta J; Cai K; Gall M; Hartwell R; Kent JD; Willis T
Biologicals; 2012 Jul; 40(4):247-53. PubMed ID: 22579294
[TBL] [Abstract][Full Text] [Related]
28. Caution in evaluation of removal of virus by filtration: Misinterpretation due to detection of viral genome fragments by PCR.
Tsujikawa M; Ohkubo Y; Masuda M; Tanaka H; Takahashi K; Sasaki Y; Yunoki M; Ikuta K
J Virol Methods; 2011 Dec; 178(1-2):39-43. PubMed ID: 21871924
[TBL] [Abstract][Full Text] [Related]
29. Qualification of a novel inline spiking method for virus filter validation.
Lutz H; Chang W; Blandl T; Ramsey G; Parella J; Fisher J; Gefroh E
Biotechnol Prog; 2011; 27(1):121-8. PubMed ID: 20878721
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic evaluation of virus clearance by depth filtration.
Venkiteshwaran A; Fogle J; Patnaik P; Kowle R; Chen D
Biotechnol Prog; 2015; 31(2):431-7. PubMed ID: 25683459
[TBL] [Abstract][Full Text] [Related]
31. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
32. Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis.
Evtushenko M; Wang K; Stokes HW; Nair H
Electrophoresis; 2005 Jan; 26(1):28-34. PubMed ID: 15624167
[TBL] [Abstract][Full Text] [Related]
33. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.
Adan-Kubo J; Tsujikawa M; Takahashi K; Hongo-Hirasaki T; Sakai K
Biotechnol Prog; 2019 Nov; 35(6):e2875. PubMed ID: 31228338
[TBL] [Abstract][Full Text] [Related]
34. Infectious prion protein in the filtrate even after 15 nm filtration.
Yunoki M; Tanaka H; Urayama T; Kanai Y; Nishida A; Yoshikawa M; Ohkubo Y; Kawabata Y; Hagiwara K; Ikuta K
Biologicals; 2010 Mar; 38(2):311-3. PubMed ID: 19931469
[TBL] [Abstract][Full Text] [Related]
35. The evolution of down-scale virus filtration equipment for virus clearance studies.
Wieser A; Berting A; Medek C; Poelsler G; Kreil TR
Biotechnol Bioeng; 2015 Mar; 112(3):633-7. PubMed ID: 25220795
[TBL] [Abstract][Full Text] [Related]
36. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
37. Scrapie removal using Planova virus removal filters.
Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
[TBL] [Abstract][Full Text] [Related]
38. Membrane filtration for virus removal.
Brandwein H; Aranha-Creado H
Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
[TBL] [Abstract][Full Text] [Related]
39. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
40. Investigations of prion and virus safety of a new liquid IVIG product.
Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
